175 results match your criteria: "Centre hospitalier de Valence[Affiliation]"
Bull Cancer
December 2024
Unité Transversale d'Education Thérapeutique, centre hospitalier de Valence, Valence, France. Electronic address:
Sexual health is a central aspect of the well-being and quality of life of cancer patients. Through two separate surveys, one conducted among patients and the other among professionals, we assessed the needs and practices relating to sexual health in cancer care. The results showed that the importance attached to taking intimate and sexual life into account was fairly high, but that 44% of patients had discussed the subject with a professional, and the majority had done so on their own initiative.
View Article and Find Full Text PDFHistopathology
December 2024
Pathology Department, CHU de Bordeaux, Bordeaux, France.
Orthod Craniofac Res
September 2024
Centre Hospitalier de Valence, Service ORL, Valence cedex, France.
Objectives: Oral appliance (OA) has been increasingly used for the treatment of obstructive sleep apnoea hypopnea syndrome (OSAHS). OAs work by propelling the mandible, increasing the upper airway calibre and reducing collapsibility. While they have shown efficacy in reducing OSAHS, long-term use can lead to adverse effects, such as dental displacement.
View Article and Find Full Text PDFSupport Care Cancer
September 2024
Centre Des Sciences du Goût Et de L'Alimentation, 9E Boulevard Jeanne d'Arc, Dijon, France.
Purpose: Metallic taste (MT) is frequently observed during head and neck cancer treatments, but very little is known about its impact on nutritional status. The aim of this study was to explore the impact of MT on the quality of life and nutritional status in patients with head and neck cancer expressing MT.
Methods: Questionnaires on quality of life, MT, weight, and food intake were filled out by 44 patients with head and neck cancer before, during, and up to 1 year after their treatment.
Neuromuscul Disord
September 2024
Centre de Référence des maladies Neuromusculaires Nord/Est/Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, APHP, 47-83 bd de l'Hôpital, Paris 75013, France. Electronic address:
TIA1/SQSTM1 myopathy is one of the few digenic myopathies. We describe four new French adult male patients carrying the TIA1 p.Asn357Ser and SQSTM1 p.
View Article and Find Full Text PDFGenes (Basel)
May 2024
Unité Pathologies Métaboliques, Érythrocytaires et Dépistage Périnatal, Service de Biochimie et Biologie Moléculaire, Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, 69500 Bron, France.
Hereditary sensory and autonomic neuropathy type 1 is an autosomal dominant neuropathy caused by the or variants. These variants modify the preferred substrate of serine palmitoyl transferase, responsible for the first step of sphingolipids synthesis, leading to accumulation of cytotoxic deoxysphingolipids. Diagnosis of HSAN1 is based on clinical symptoms, mainly progressive loss of distal sensory keep, and genetic analysis.
View Article and Find Full Text PDFClin Genet
October 2024
Department of Genetics, Clinical Genetics Unit, Centre de Référence Maladies Rares des Anomalies du Développement Sud-Est, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Bron, France.
Microcephalic osteodysplastic primordial dwarfism type I (MOPDI) is a very rare and severe autosomal recessive disorder characterized by marked intrauterine growth retardation, skeletal dysplasia, microcephaly and brain malformations. MOPDI is caused by biallelic mutations in RNU4ATAC, a non-coding gene involved in U12-type splicing of 1% of the introns in the genome, which are recognized by their specific splicing consensus sequences. Here, we describe a unique observation of immunodeficiency in twin sisters with mild MOPDI, who harbor a novel n.
View Article and Find Full Text PDFBull Cancer
September 2024
Unité transversale d'éducation des patients, centre hospitalier de Valence, 179, boulevard du Maréchal-Juin, 26953 Valence, France.
Introduction: The post-cancer period is a delicate one, as it does not necessarily mean good health and/or a return to life as it was "before". Over the past twenty years, a number of initiatives have been launched to improve support for people after cancer. We have created a post-cancer care pathway for patients with head and neck cancer, based on a nursing interview and the use of a post-cancer grid.
View Article and Find Full Text PDFJ Oral Rehabil
June 2024
Centre Hospitalier de Valence, Service d'ORL et de Chirurgie Cervicofaciale, Valence, France.
Background: Limitation of mouth opening, widely known as trismus, is a major symptom altering quality of life in individuals presenting from temporomandibular joint disorder or head and neck cancer. A French-language instrument addressing jaw opening limitation following treatment for head and neck cancer (HNC) or temporomandibular joint disorder (TMD) is lacking.
Objective: The aim of this study was to translate and validate the Gothenburg Trismus Questionnaire-2 (GTQ-2) into French.
Neurol Neuroimmunol Neuroinflamm
March 2024
From the Service de neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation (G.A., P.N., R.M., S.V.), Centre de Ressources, Recherche et Compétence sur la Sclérose en Plaques et Fondation Eugène Devic EDMUS pour la Scléros; Ramsay Santé (G.A., L.G.), Clinique de la Sauvegarde, Lyon; Centre Hospitalier de Valence (L.N.), Service de Neurologie, Valence, France; Sorbonne Université (D.P., C.B.), Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2- Mazarin, Paris, France; OncoNeuroTox Group; Aix Marseille Université (J.P.), APHM, Hôpital de la Timone, Department of Neurology, Marseille; Neurology Department (Y.B., R.D., E.M., T.R.), CRCSEP Paris, Pitié-Salpêtrière Hôpital, APHP; CHU de Caen Normandie (P.B.), Service de Neurologie, Caen; CHU de Toulouse (J.C.), CRC-SEP, Department of Neurology, F-31059 Toulouse Cedex 9; Université Toulouse III, Infinity, INSERM UMR1291 - CNRS UMR5051, F-31024 Toulouse Cedex 3; Polyclinique des Alpes du Sud (Y.D.), Gap, France; Claude Bernard Lyon 1 University (C.F.T.), Lyon Neuroscience Research Center CRNL U1028 UMR 5292, IMPACT F-69500 and Neuro-Ophthalmology Unit, Hospices Civils de Lyon, Neurological Hospital; Centre Hospitalier de Chambéry (C.G.-J.), Service de Neurologie, Chambéry; MeLiS - UCBL-CNRS UMR 5284 - INSERM U1314 (B.J.), Université Claude Bernard Lyon 1; ImmuCare, Institute of Cancerology, Hospices Civils de Lyon, France; Department of Neurology, Hôpital Lyon Sud, Hospices Civils de Lyon; Service de Neurologie (P.K.), Centre Hospitalier de Luxembourg, L-1210 Luxembourg-Ville, Luxembourg; Department of Neurology (A.K.), Lille Catholic University, Lille Catholic Hospitals, FHU PRECISE; CRCSEP Nice (C.L.-F.), UMR2CA-URRIS, Université Nice Côte d'Azur, Neurologie CHU de Nice Pasteur 2; Department of Medical Oncology (A.M.), Centre Léon Bérard, Lyon, France; Université Claude Bernard Lyon 1 (R.M.), Villeurbanne; Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle (R.M., S.V.), Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon; and Centre des Neurosciences de Lyon (S.V.), INSERM 1028 et CNRS UMR5292, Observatoire Français de la Sclérose en Plaques, Lyon, France.
Objectives: Immune checkpoint inhibitors (ICIs) are increasingly used in cancer treatment. Their mechanism of action raises the question of possible exacerbation of preexisting multiple sclerosis (MS). The aim of our study was to assess the risk of increased MS activity, defined by the occurrence of a relapse and/or a new MRI lesion, after ICI initiation.
View Article and Find Full Text PDFFront Cardiovasc Med
January 2024
Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, France.
Bull Cancer
April 2024
Département APA-S, laboratoire sur les vulnérabilités et l'innovation dans le Sport (L-ViS, EA-7428), UFR STAPS, université Lyon1 - UFR STAPS, 27-29, boulevard du 11 nov 1918, 69622 Villeurbanne cedex, France.
Context: In our institution, patients with upper aero-digestive tract cancer receive adapted physical activity (APA) awareness training as part of their holistic oncology care program. The main aim of this study was to show that raising awareness of APA helped to increase self-reported PA levels, as assessed by questionnaire.
Method: This retrospective study included 67 patients with localized Head and Neck cancer.
J Interv Cardiol
January 2024
Department of Cardiology, Clinique Saint Hilaire, Rouen, France.
Objectives: The aim of this postmarket clinical study was to assess the safety and efficacy of the latest generation polymer-free sirolimus-eluting stents (PF-SES) in an all-comers population comparing outcomes in stable coronary artery disease (CAD) versus acute coronary syndrome (ACS) in France.
Background: The efficacy and safety of the first-generation PF-SES have already been demonstrated by randomized controlled trials and "all-comers" observational studies.
Methods: For this all-comers observational, prospective, multicenter study, 1456 patients were recruited in 22 French centers.
Ann Pharm Fr
May 2024
Service pharmacie, groupement hospitalier nord, hospices civils de Lyon, Lyon, France.
Background: Invasive aspergillosis (IA) is increasing especially in new groups of patients. Despite advances in management, morbidity and mortality related to IA remain high. Thus, Clinical Decision Support System (CDSS) dedicated to IA are needed to promote the optimal antifungal for each group of patients.
View Article and Find Full Text PDFEur Ann Otorhinolaryngol Head Neck Dis
August 2024
Service d'ORL et de Chirurgie Cervicofaciale, Centre Hospitalier de Valence, 179, boulevard du Maréchal-Juin, 26953 Valence, France. Electronic address:
Aims: Inferior meatus augmentation by injection or implants is one of the treatments for empty-nose syndrome (ENS), but levels of evidence of efficacy are low. We present the technique and evaluate our experience. The primary objective was to analyze changes in Empty Nose Syndrome 6-item Questionnaire (ENS6Q) scores after treating patients with ENS by autologous fat injection.
View Article and Find Full Text PDFBMJ Med
October 2023
Etablissement Francais du Sang, La Plaine Saint-Denis, France.
Eur J Hum Genet
February 2024
Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Biostatistics, F-76000, Rouen, France.
Psychiatr Genet
October 2023
Centre de Référence Maladies Rares Troubles du Comportement d'Origine Génétique (GénoPsy Lyon), Centre d'excellence autisme iMIND, Centre Hospitalier Le Vinatier, 95 Boulevard Pinel, 69500 Bron, France et UMR 5229, CNRS & Université Lyon 1.
Sleep Breath
March 2024
Service ORL, Centre Hospitalier de Valence, 179 Boulevard du Maréchal Juin, 26953, Valence, cedex, France.
Purpose: In France, oral appliances (OAs) are the first-line treatment for moderate and second-line treatment for severe obstructive sleep apnea-hypopnea syndrome. In general, the sleep specialist refers his/her patient to the appliance specialist for the impressions and the fitting. However, is there a relationship between the volume of activity of the appliance specialist and the efficacy of this device?
Methods: Our unit includes seven appliance otolaryngology specialists whose activities are highly variable (number of patients varying by a factor of almost 10).
Ann Pathol
March 2024
Service d'anatomie et cytologie pathologiques du centre hospitalier de Valence, 179, boulevard du Maréchal-Juin, 26000 Valence, France.
Pediatrics
July 2023
Hôpital Femme Mère Enfant, Service d'Endocrinologie Pédiatrique et Pédiatrie Générale, Hospices Civils de Lyon, Bron, France.
J Clin Pharmacol
November 2023
Octapharma France SAS, Boulogne-Billancourt, France.
Human fibrinogen concentrate (Fibryga) received temporary approval for fibrinogen replacement therapy in France (2017), with subsequent full approval for congenital and acquired hypofibrinogenemia. We evaluated real-world use for on-demand treatment of bleeding and prophylaxis to enhance our knowledge on fibrinogen concentrate as an option for fibrinogen replacement. Data were retrospectively collected from adult and pediatric patients with fibrinogen deficiency.
View Article and Find Full Text PDFKidney Int
August 2023
Laboratoire des Maladies Rénales Héréditaires, Inserm UMR 1163, Institut Imagine, Université Paris Cité, Paris, France; Service de Médecine Génomique des Maladies Rares, Hôpital Necker-Enfants Malades, Assistance Publique, Hôpitaux de Paris (AP-HP), Paris, France. Electronic address:
X-linked Alport syndrome (XLAS) is an inherited kidney disease caused exclusively by pathogenic variants in the COL4A5 gene. In 10-20% of cases, DNA sequencing of COL4A5 exons or flanking regions cannot identify molecular causes. Here, our objective was to use a transcriptomic approach to identify causative events in a group of 19 patients with XLAS without identified mutation by Alport gene panel sequencing.
View Article and Find Full Text PDFJ Med Vasc
February 2023
Club des jeunes hypertensiologues, France; Service de néphrologie, CHU de Tours, Tours, France; Inserm U1246 SPHERE, université de Nantes, université de Tours, Tours, France; FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France. Electronic address:
Background: Resistant hypertension (RHT) is a major health care concern affecting 20 to 30% of hypertensive patients and increasing cardiovascular risk. Recent renal denervation trials have suggested a high prevalence of accessory renal arteries (ARA) in RHT. Our objective was to compare the prevalence of ARA in RHT vs.
View Article and Find Full Text PDF